StockpollyBeta
Get App
Delisting riskPopularity #4,982Earnings today
BRTX · NASDAQ · Biotechnology

BioRestorative Therapies (BRTX)

Develops autologous cell therapies and cell-secretome cosmetics for spine and metabolic applications.

$2.62
After hours−0.05 (−1.87%)
At close$2.67(−1.48%)

  1. BioRestorative Therapies Announces Reverse Stock Split

    GlobeNewsWireStock split

  2. BioRestorative Therapies Announces Completion of BRTX-100 Phase 2 Manufacturing, Highlighting Integrated Regenerative Biologics Platform

    GlobeNewsWire

  3. BioRestorative Therapies Strengthens Leadership with Appointment of Healthcare Executive Zachary Smith as Vice President of Biocosmeceuticals Division to Accelerate Commercial Expansion and Strategic Growth

    GlobeNewsWire

  4. Kaos Capital Announces Acquisition of 4.9% Stake in BioRestorative Therapies (NASDAQ: BRTX)

    PRNewsWire

  5. BioRestorative Completes Phase 2 Dosing of BRTX-100, Advancing Lead Regenerative Spine Program Toward 2027 Topline Data

    Globe News Wire

  6. BioRestorative Completes Phase 2 Dosing of BRTX-100, Advancing Lead Regenerative Spine Program Toward 2027 Topline Data

    GlobeNewsWire

  7. What Makes Biorestorative Therapies (BRTX) a New Buy Stock

    Zacks Investment Research

  8. BioRestorative Therapies Presents New Preclinical Data at ISCT 2026 Highlighting Source-Specific Exosome Functionality and Commercial Applications in BioCosmeceuticals

    Globe News Wire

  9. BioRestorative Therapies Presents New Preclinical Data at ISCT 2026 Highlighting Source-Specific Exosome Functionality and Commercial Applications in BioCosmeceuticals

    GlobeNewsWire

  10. BioRestorative Therapies Reports Expanded Phase 2 Blinded Dataset for BRTX-100 Showing Sustained Pain and Functional Improvements in Chronic Lumbar Disc Disease

    GlobeNewsWire

  11. BioRestorative Therapies to Present New Data at ISCT 2026 Highlighting Its Ongoing Phase 2 Clinical Trial in Chronic Lumbar Disease and Its BioCosmeceutical Platform

    GlobeNewsWire

  12. Here's Why Biorestorative Therapies (BRTX) Looks Ripe for Bottom Fishing

    Zacks Investment Research

  13. BioRestorative Therapies Announces Strategic Collaboration with 203 Creates to Build and Commercialize Biocosmeceutical Platform

    GlobeNewsWire

  14. BioRestorative Therapies Reports Positive Phase 2 Blinded Data for BRTX-100 Demonstrating Meaningful Improvements in Pain and Function in Chronic Lumbar Disc Disease

    GlobeNewsWire

  15. Biorestorative Therapies, Inc. (BRTX) Reports Q4 Loss, Lags Revenue Estimates

    Zacks Investment Research

  16. BioRestorative Therapies to Present Positive Phase 2 Blinded Data for BRTX-100 Demonstrating Meaningful Improvements in Pain and Function in Chronic Lumbar Disc Disease

    GlobeNewsWire

  17. BioRestorative Therapies (OTCMKTS:BRTX) Share Price Passes Below Fifty Day Moving Average – Here’s Why

    Defense World

  18. BioRestorative Announces Closing of $5.0 Million Public Offering

    GlobeNewsWire

  19. BioRestorative Announces Pricing of $5.0 Million Public Offering

    GlobeNewsWire

  20. BioRestorative Announces Positive Outcome from Type B Meeting with FDA

    GlobeNewsWire